Benzinga | Oct 27, 2020 07:53AM EDT

Moleculin To Participate In Panel At ROTH Capital's 'COVID-19 Therapeutics in Development' Healthcare Event Oct. 28 12:00-1:20 pm ET

HOUSTON, Oct. 27, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced that members of management will participate in a panel at ROTH Capital's healthcare event titled, "COVID-19 Therapeutics in Development," taking place on Wednesday, October 28th, 2020.

Details of Moleculin's panel participation are as follows:

Session title: "Indirect Antivirals Against SARS-CoV2 Virus"

Date: Wednesday, October 28th, 2020

Time: 12:00 - 1:20 pm ET

To register for the event, please click here.